To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
August 12, 2010 > Novel findings about non-coding lincRNAs
John L. Rinn, PhD (Damon Runyon-Rachleff Innovator ‘09-‘11, Damon Runyon Fellow ‘05-‘07) of Harvard Medical School and the Broad Institute, Boston, Laura D. Attardi, PhD (Damon Runyon Scholar ‘02-‘04) of Stanford University, Stanford, and colleagues, discovered that one particular non-coding RNA, lincRNA-p21, acts as a repressor of p53-dependent gene expression and apoptosis (cell death). p53 is the most commonly-mutated gene in human cancers. These findings were published in the journal Cell. In a separate study, Howard Y. Chang, MD, PhD (Damon Runyon Scholar ‘06-‘08, former Fellowship Sponsor) and colleagues at Stanford University, Stanford, reported that lincRNAs may function by serving as scaffolds to bring together select enzymes that regulate the expression of target genes by modifying histones. This report was published in the journal Science.